New breast cancer trial aims to skip chemo for some patients

NCT ID NCT07616427

Recruiting now Disease control Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new drug called fovinaciclib combined with hormone therapy and targeted antibodies in people with early-stage HR-positive/HER2-positive breast cancer. After 6 weeks, doctors check if the tumor is shrinking. If it is, patients continue the same treatment; if not, they switch to standard chemotherapy before surgery. The goal is to see if this approach can cure as many people as standard care while sparing some from chemotherapy side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HR+/HER2- EARLY BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hormone receptor-positive breast cancer triple-positive breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HR+/HER2- EARLY BREAST CANCER

Contacts and locations

Locations

2nd Affiliated Hospital, School of Medicine
RECRUITING

Hangzhou, Zhejiang, 310009, China
Ningbo No. 2 Hospital
RECRUITING

Ningbo, Zhejiang, 315010, China
The First Affiliated Hospital of Nanjing Medical University
RECRUITING

Nanjing, Jiangsu, 210029, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.